EAM
PBYI icon

EverPoint Asset Management’s Puma Biotechnology PBYI Stock Holding History

EverPoint Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$190K Sell
6,188
-203,812
-97% -$8.81M ﹤0.01% 395
2016
Q3 		$14.1M Sell
210,000
-240,000
-53% -$12.1M 0.25% 104
2016
Q2 		$13.4M Buy
+450,000
New +$14.1M 0.26% 113
2015
Q2 		– Sell
-8,250
Closed -$1.95M – 552
2015
Q1 		$1.95M Buy
+8,250
New +$1.76M 0.04% 415

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

EverPoint Asset Management's PBYI Position: Q4 2016 in Review

EverPoint Asset Management reduced its Puma Biotechnology (PBYI) stake by 97% in Q4 2016, selling an estimated $8.81M and leaving 6,188 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #395.

EverPoint Asset Management first reported a position in PBYI in Q1 2015 and has held it in 4 quarters since. The position peaked at $14.1M in Q3 2016. 128 funds tracked by Wall St. Rank hold PBYI as of Q4 2016.

  • EverPoint Asset Management held 6,188 shares of Puma Biotechnology worth $190K as of Q4 2016.
  • EverPoint Asset Management sold 203,812 Puma Biotechnology shares in Q4 2016, an estimated $8.81M.
  • Puma Biotechnology made up ﹤0.01% of EverPoint Asset Management's portfolio in Q4 2016, its #395 holding.
  • EverPoint Asset Management first reported a position in Puma Biotechnology in Q1 2015 and has held it in 4 quarters since.
  • EverPoint Asset Management's Puma Biotechnology position peaked at $14.1M in Q3 2016.
  • 128 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.